par Wolking, Stefan;Campbell, Ciarán;Stapleton, Caragh;McCormack, Mark;Delanty, Norman;Depondt, Chantal ;Johnson, Michael;Koeleman, Bobby B.P.C.;Krause, Roland;Kunz, Wolfram W.S.;Marson, Anthony Guy;Sander, Josemir W;Sills, Graeme;Striano, Pasquale;Zara, Federico;Sisodiya, Sanjay;Cavalleri, Gianpiero;Lerche, Holger
Référence Frontiers in Pharmacology, 12, 688386
Publication Publié, 2021-06
Référence Frontiers in Pharmacology, 12, 688386
Publication Publié, 2021-06
Article révisé par les pairs
Résumé : | Objective: Resistance to anti-seizure medications (ASMs) presents a significant hurdle in the treatment of people with epilepsy. Genetic markers for resistance to individual ASMs could support clinicians to make better-informed choices for their patients. In this study, we aimed to elucidate whether the response to individual ASMs was associated with common genetic variation. Methods: A cohort of 3,649 individuals of European descent with epilepsy was deeply phenotyped and underwent single nucleotide polymorphism (SNP)-genotyping. We conducted genome-wide association analyses (GWASs) on responders to specific ASMs or groups of functionally related ASMs, using non-responders as controls. We performed a polygenic risk score (PRS) analyses based on risk variants for epilepsy and neuropsychiatric disorders and ASM resistance itself to delineate the polygenic burden of ASM-specific drug resistance. Results: We identified several potential regions of interest but did not detect genome-wide significant loci for ASM-specific response. We did not find polygenic risk for epilepsy, neuropsychiatric disorders, and drug-resistance associated with drug response to specific ASMs or mechanistically related groups of ASMs. Significance: This study could not ascertain the predictive value of common genetic variants for ASM responder status. The identified suggestive loci will need replication in future studies of a larger scale. |